Big Pharmas remain stuck to the idea of molecular glue degraders. The latest company to see an opportunity is Japan’s Eisai, which has signed a $1.5 billion biobucks pact with SEED Therapeutics ...

Eisai plants molecular glue SEED with $1.5B biobucks deal in neuro, oncology Molecular glues are small molecules used to stabilize the interaction between two proteins that traditionally don’t ...

This is the first study to identify and develop small molecules—termed "molecular glues"—that enhance the interaction between ...

These studies provide insights into two areas: discovering new "molecular glues" and understanding the impact of genetic mutations within cancer cells, setting the stage for therapeutic approaches.

This is the first study to identify and develop small molecules -- termed "molecular glues" -- that enhance the interaction between ChREBPα and 14-3-3 proteins in pancreatic beta cells.

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Over 10+ companies are evaluating 12+ molecular glues in various stages of development, and their anticipated acceptance in the oncology market would significantly increase market revenue.

Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Molecular Glues - Competitive Landscape, 2025" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...